Although the evidence of the renoprotective effects of the FXa inhibitor in DKD is still absent, a meta-analysis offered some hints of the safety and efficacy of orally administered edoxaban in patients with both atrial fibrillation (AF) and CKD (114). The gene discussed is F10; the disease is diabetic kidney disease.